Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
Category:
Published on: 5 Mar 2018
You’re about to turn 60, and you’re fretting. Your mother has had Alzheimer’s disease since the age of 65. At what age will the disease strike you? A Canadian study published in JAMA Neurology shows that the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer’s, the more likely they are to have amyloid plaques, the cause of the cognitive decline associated with the disease, in their brain.
Category:
Published on: 26 Feb 2018
Canadian Open Neuroscience Platform will make disseminating and publishing data easier
Modern neuroscience research can produce massive amounts of data, which researchers can use to find patterns revealing anything from the first physiological signs of Alzheimer’s disease to a new drug target that could stop neurodegeneration. However, this data must be stored, processed, and distributed effectively.
Category:
Published on: 19 Feb 2018
Volume in brain region linked to physiological changes characteristic of AD
New research has drawn a link between changes in the brain’s anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer’s disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
Category:
Published on: 19 Dec 2017
NeuroSGC created to increase volume and quality of cell assays for drug discovery
A new partnership between the Structural Genomics Consortium (SGC) and the Montreal Neurological Institute and Hospital (The Neuro) will use a unique open science framework to help scientists discover new targets for drug development for neurological diseases.
The partnership, called NeuroSGC, will initially focus on Parkinson’s disease and amyotrophic lateral sclerosis (ALS), two of the most common neurodegenerative diseases.
Category:
Published on: 6 Dec 2017
Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Category:
Published on: 4 Dec 2017
Senate of Canada recognizes outstanding contributions to the community
The Senate of Canada has awarded Alan Evans a Canada 150 medal for his commitment to advancements in Alzheimer’s disease and palliative care research. He was nominated by Senator Judith Seidman, a former research fellow at the Montreal Neurological Institute and Hospital, and Associate Professor of the McGill School of Social Work.
Published on: 27 Nov 2017
Grants for Heather Durham, Stefano Stifani and Jay Ross total just over $2 million
Three MNI researchers have received grants from the ALS Society of Canada worth a total of more than $2 million.
Category:
Published on: 24 Nov 2017
Brain stimulation can change how much we enjoy and value music
Enjoyment of music is considered a subjective experience; what one person finds gratifying, another may find irritating. Music theorists have long emphasized that although musical taste is relative, our enjoyment of music, be it classical or heavy metal, arises, among other aspects, from structural features of music, such as chord or rhythm patterns that generate anticipation and expectancy.
Category:
Published on: 20 Nov 2017
The Azrieli Centre for Autism Research will foster innovations in therapy and a better understanding of Autism Spectrum Disorder.
A new research centre in Montreal will help lift the shroud of mystery surrounding autism spectrum disorder (ASD), and lead to the development of better diagnostic tools and more effective therapies for people with autism.
Category:
Published on: 23 Oct 2017
A Brilliant Night has donated a total of $1.6 million since 2015
A night dedicated to the memory of those lost to brain cancer and in honour of those still fighting the disease will raise money for research that will lead to better treatments.
Category:
Published on: 10 Oct 2017
Research shows how the brain’s motor signals sharpen our ability to decipher complex sound flows
Whether it is dancing or just tapping one foot to the beat, we all experience how auditory signals like music can induce movement. Now new research suggests that motor signals in the brain actually sharpen sound perception, and this effect is increased when we move in rhythm with the sound.
Category:
Published on: 5 Oct 2017
Discovery points to possible target for cancer drugs
McGill University researchers have discovered a mechanism through which mitochondria, the energy factory of our body’s cells, play a role in preventing cells from dying when the cells are deprived of nutrients – a finding that points to a potential target for next-generation cancer drugs.
The research, published in Molecular Cell, builds on previous work by McGill professor Nahum Sonenberg, one of the senior authors of the new study.
Category:
Published on: 22 Sep 2017
Research symposium, public education event and ALS walk planned
Multiple events planned for this week will help educate the public about amyotrophic lateral sclerosis (ALS), a devastating disease that still has no cure.
Category:
Published on: 13 Sep 2017
Society recognizes scholarly, research and artistic excellence.
Dr. Edith Hamel and Dr. Robert Zatorre have been elected Fellows of the Royal Society of Canada. Election to the academies of the Royal Society of Canada is the highest honour a scholar can achieve in the Arts, Humanities and Sciences.
Category:
Published on: 7 Sep 2017
Pages
